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SUMMARY
Germlinemutations in the fumarate hydratase (FH) tumor suppressor gene predispose to leiomyoma-
tosis, renal cysts, and renal cell cancer (HLRCC). HLRCC tumors overexpress HIF1a and hypoxia
pathway genes. We conditionally inactivated mouse Fh1 in the kidney. Fh1 mutants developed
multiple clonal renal cysts that overexpressed Hif1a and Hif2a. Hif targets, such as Glut1 and Vegf,
were upregulated. We found that Fh1-deficient murine embryonic stem cells and renal carcinomas
from HLRCC showed similar overexpression of HIF and hypoxia pathway components to the mouse
cysts. Our data have shown in vivo that pseudohypoxic drive, resulting from HIF1a (and HIF2a)
overexpression, is a direct consequence of Fh1 inactivation. Our mouse may be useful for testing
therapeutic interventions that target angiogenesis and HIF-prolyl hydroxylation.INTRODUCTION
The FH tumor suppressor gene encodes the Krebs cycle
enzyme fumarate hydratase and is mutated in individuals
with the Mendelian syndrome of hereditary leiomyomato-
sis and renal cell cancer (HLRCC) (Tomlinson et al., 2002;
Toro et al., 2003). Individuals with HLRCC develop benignsmooth-muscle neoplasms of the skin and uterus and may
develop solitary renal cell cancers, of type II papillary or
collecting-duct morphology (Alam et al., 2003; Kiuru and
Launonen, 2004; Kiuru et al., 2001; Tomlinson et al.,
2002; Toro et al., 2003). A few HLRCC patients may also
develop leiomyosarcomas and many develop benign
renal cysts (Lehtonen et al., 2005). Most HLRCC tumorsSIGNIFICANCE
HIF overexpression occurs (1) in renal cancers from the familial cancer syndrome HLRCC, which results from
germline mutations in the Krebs cycle gene fumarate hydratase (FH), and (2) in cancers from von Hippel-Lindau
disease patients. In vitro inactivation of FH leads to HIF1a overexpression. Here, we directly link kidney-specific,
biallelic inactivation of murine Fh1 to pseudohypoxic drive in vivo. Like humans with HLRCC, Fh1/ animals
develop renal cysts. These cysts are clonal and proliferative, and they show overexpression of HIF and hypoxia
pathway components. This overexpression is also seen in Fh1/ ES cells. Our mouse model advances the under-
standing of biochemical pathways linking mitochondrial dysfunction and tumorigenesis and will allow testing of
potential therapies for renal neoplasms.Cancer Cell 11, 311–319, April 2007 ª2007 Elsevier Inc. 311
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Renal Cyst Development in Fh1-Deficient Miceexhibit activation of the hypoxia pathway: they overex-
press hypoxia-inducible factor-1-a (HIF1a) and its target
genes, such as vascular endothelial growth factor (VEGF)
and BNIP3, and have increased vascularity in comparison
to their sporadic counterparts (Pollard et al., 2005a,
2005b). This evidence suggests that ‘‘pseudohypoxic
drive’’—that is, constitutive expression of HIF1a in nor-
moxia—plays a significant role in the pathogenesis of
HLRCC neoplasms. Indeed, pseudohypoxia is evident in
the pathogenesis of other familial cancers such as those
in von Hippel-Lindau (VHL) disease (Iliopoulos and Kaelin,
1997; Maher and Kaelin, 1997) and hereditary paragan-
gliomatosis (HPGL) (Gimenez-Roqueplo et al., 2001,
2002; Pollard et al., 2005b), the latter arising in patients
with germline succinate dehydrogenase (SDHB/C/D) mu-
tations (Baysal et al., 2002).
HIF is a transcription factor that is activated in all cells
when oxygen tension is low, and VHL acts as the recogni-
tion component of an ubiquitin E3 ligase complex that in-
activates HIF in the presence of oxygen (Ivan et al., 2001;
Jaakkola et al., 2001; Lisztwan et al., 1999; Maxwell et al.,
1999). HIF was originally identified from studies of the
erythropoietin gene but is now recognized to regulate a
very wide range of other genes, including those encoding
proteins involved in glucose metabolism and angiogene-
sis (Carmeliet et al., 1998; Pugh and Ratcliffe, 2003). A
HIF complex consists of a regulatory a subunit and a con-
stitutively expressed b subunit (Wang et al., 1995). Under
well-oxygenated conditions, VHL acts as a recognition
molecule that targets HIFa subunits for proteosomal deg-
radation. Two specific proline residues in the oxygen-
dependent degradation domain (ODDD) of HIF1a and an
asparagine in the transactivation domain are respectively
hydroxylated by the dioxygenases PHD1-3 and FIH (Ivan
et al., 2001; Jaakkola et al., 2001; Masson and Ratcliffe,
2003; Schofield and Ratcliffe, 2004). Prolyl hydroxylation
within the ODDD allows VHL to interact with the HIFa sub-
unit, leading to its ubiquitylation and destruction. Aspara-
ginyl hydroxylation prevents transactivator recruitment,
thus inactivating HIF through a second route (Masson
and Ratcliffe, 2003). When the level of oxygen is low,
HIFa subunits are protected from hydroxylation, dimerize
with a b subunit to form a HIF complex and interact with
hypoxic response elements in promoter/enhancer re-
gions, and recruit coactivators to modulate the expression
of a large number of genes (Carmeliet et al., 1998; Talks
et al., 2000)
We have shown that HLRCC tumors accumulate fuma-
rate and succinate in vivo (Pollard et al., 2005b). In vitro
studies have demonstrated that siRNA knockdown (and
biochemical inhibition) of FH and SDH can cause failure
of the PHDs to hydroxylate HIF1a (Isaacs et al., 2005; Se-
lak et al., 2005) because this reaction relies on conversion
of a-ketoglutarate to succinate. Such in vitro studies inev-
itably have well-characterized limitations, such as the in-
ability to study the tissue environment or the cell of origin
of the human tumors and the abnormal (epi)genetic com-
plement of most cultured cells, especially if derived from
tumors. Moreover, there is no commercially available spe-312 Cancer Cell 11, 311–319, April 2007 ª2007 Elsevier Inc.cific pharmacological inhibitor of FH, forcing reliance on
3-nitropropionic acid (3-NPA), a molecule that also inhibits
SDH (Binienda et al., 2001; Selak et al., 2005; Zeevalk
et al., 1995).
In order to provide a model of HLRCC, and potentially
a more general model of Krebs cycle dysfunction in tumor-
igenesis, we constructed an Fh1 ‘‘knockout’’ mouse.
RESULTS
We created a conditionally targeted Fh1 mutant allele
(Fh1fl), thus facilitating tissue-specific and/or temporal
biallelic Fh1 inactivation (Figure 1) and analysis of the
downstream functional consequences. Fh1/ mice died
in early embryogenesis (Figure 2). In order to study spe-
cific inactivation of Fh1 in the kidney, Fh1fl/+ mice were
bred with mice expressing Cre recombinase under the
Ksp-Cadherin promoter (Ksp1.3/Cre) (Shao et al., 2002a,
2002b). The Fh1fl/+ Ksp1.3/Cre mice were then inter-
crossed to produce homozygous conditional knockout
Fh1fl/fl Ksp1.3/Cre progeny.
Fh1fl/fl Ksp1.3/Cre animals appeared healthy until 8
months of age, when polyuric renal failure became appar-
ent in some animals (data not shown). All other animals of
Figure 1. Targeting Strategy for the Fh1 Conditional Knock-
out Mouse
We used homologous recombination to replace the wild-type allele
with the targeted allele, flanking exons 2 and 3 of Fh1 by loxP sites
to allow conditional gene inactivation. Comparison with human
HLRCC FH mutations shows that deletion of these exons would cause
loss of protein function. The targeting construct (A) contained the pro-
karyotic neomycin resistance gene (neo) flanked by Frt sites (F) and
three arms of genomic DNA homologous to the Fh1 locus. LoxP sites
(L) flanked the 3.0 kb middle arm. This targeting construct was trans-
ferred into ES cells by electroporation, and cells were selected for
G418S resistance. ES cell clones were isolated and analyzed initially
by PCR for 30 and 50 site-specific integration into the Fh1 locus. Further
analysis of positive clones by Southern blotting confirmed the proper
integration of the targeted allele (B). Two independent clones were
used for blastocyst injection to generate chimeras from which we
obtained heterozygous F1 offspring, which were also identified by
PCR and Southern blotting (data not shown). The neomycin cassette,
flanked by Frt sites, was excised in vivo by crossing with mice express-
ing enhanced Flp recombinase under the ubiquitous phosphoglycer-
ate kinase (Pgk) promoter.
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Renal Cyst Development in Fh1-Deficient Micethis genotype (n = 26) eventually became ill, the oldest pre-
senting at 15 months of age. Postmortem examination
showed macroscopic renal cysts in all Fh1fl/fl Ksp1.3/Cre
animals (Figure 3). The kidneys showed extensive cystic
change in the cortico-medullary junction with irregular
cysts lined by cuboidal epithelium, consistent with a deri-
vation from the loop of Henle. There was, in addition, mild
hydronephrosis in animals more than 14 months old. The
proximal and distal convoluted tubules appeared grossly
normal, although occasional glomeruli were sclerosed.
Focal minor inflammatory infiltrate was minimal. Some of
Figure 2. Fh1 Null Mice Die during Early Embryogenesis
Fh1fl/+ mice were bred with Pgk-Cre+/ mice to generate heterozygous
Fh1+/ knockout mice. To obtain Fh1/ embryos, Fh1+/ heterozy-
gous mice were crossed. Litters were examined over a range of gesta-
tional stages with the morning of finding the plug determined as em-
bryonic day (E) 0.5. In order to discriminate between the wild-type
and the mutant alleles, the three-primer PCR analysis was used (see
Experimental Procedures) using yolk sac DNA. We genotyped 176
animals born from matings between heterozygous Fh1+/ parents, of
which 59 (33%) were Fh1+/+ and 117 (66%) were Fh1+/, with no
Fh1/ animals detected. Analysis of Fh1/ embryos indicated lethal-
ity at E6.0. At E8.0, Fh1/ (knockout) embryos had failed to develop
beyond the egg-cylinder stage and were subsequently resorbed in
utero (top; scale bar, 0.5 mm). Embryos at E7.0 were formalin fixed,
paraffin embedded, and analyzed immunohistochemically (middle
and lower; scale bar, 200 mm for all panels) for expression of laminin
and Oct-4. Wild-type (right) and mutant (left) embryos expressed
both proteins. Laminin was detected in the embryonic basement mem-
brane (arrow) and in Reichert’s membrane (parietal endoderm) (arrow-
head). Oct-4 was expressed in the primitive embryonic ectoderm
(asterisk).the tubules were lined by vacuolated epithelium contain-
ing proteinaceous debris, but most contained small
amounts of pale eosinophilic secretion, and some of the
cells lining these cysts appeared to show poor intercellular
cohesion and mild nuclear variation.
PAS staining (data not shown) revealed the cyst-lining
epithelium to be negative, in contrast to the convoluted
tubular epithelium, indicating that the cysts were derived
from the loop of Henle. The cytoplasm of the epithelial
cells lining the cysts stained negatively for aquaporin1,
positively for aquaporin2 (53.3%), and positively for
Tamm-Horsfall protein (Thp) (57.0%), showing that the
majority of cysts were derived from the collecting ducts
and the thick ascending limb of the loop of Henle (Figure 3).
Kidneys from asymptomatic Fh1fl/fl Ksp1.3/Cre animals
aged less than 10 months revealed similar cysts and
some mild pelvic dilatation. Sections taken through the
ureters appeared normal, and no organic blockage was
evident at the pelvi-ureteric junction. The medulla of the
kidneys was normal. Although most mice of all genotypes
developed microscopic (<0.5 mm diameter), age-related
renal cysts, no abnormal renal or other phenotype (Fig-
ure 3) was found in the control littermates (Cre/ and/or
Fh1+/+ animals) or in the mutant heterozygotes (Fh1fl/+;
Ksp1.3-Cre+/).
In order to confirm Cre-mediated Fh1 deletion in the
renal cysts, we used in situ hybridization (ISH) to show ab-
sence of Fh1mRNA specifically in the cells lining the cysts
(Figure 4). Additionally, five cysts were isolated using la-
ser-capture microdissection and PCR genotyped for the
targeted and deleted Fh1 allele. All cysts showed absence
of the targeted allele and the presence of the recombined
(deleted) allele (1 flox) (Figure 4). By comparison, adjacent
renal cortex showed the presence of the targeted (func-
tional) Fh1 allele (termed 2 flox); in some cases, the de-
leted allele was also present (Figure 4), showing that
Cre-mediated recombination of at least one allele had oc-
curred in some morphologically normal cells, and that
‘‘two hits’’ were necessary for cyst formation.
In order to test whether the cysts were derived from the
proliferation of a single cell, we used enzyme histochem-
istry to search for loss of mitochondrial cytochrome c ox-
idase, a rare phenomenon that occurs spontaneously with
age. This method has been used previously to demon-
strate clonal origins in the gastrointestinal tract (Greaves
et al., 2006). No loss of cytochrome c oxidase activity
was observed in kidneys from wild-type mice or in non-
cystic tissue from knockout animals, showing polyclonal
origins. However, occasional absence of activity was
found in cysts from knockout animals (Figure 5). Smaller
cysts showed uniform loss of activity in the cyst epithe-
lium, demonstrating monoclonal origin. Some larger cysts
showed patches of absent activity, together with patches
of normal activity. Given that cytochrome c oxidase inac-
tivation is a very rare event (<1 in 200 cysts), by far the
most probable explanation for the ‘‘mixed’’ larger cysts
was fusion between smaller cysts.
Renal cysts from ten animals (five knockouts and five
Fh1 wild-type littermate controls) were analyzed forCancer Cell 11, 311–319, April 2007 ª2007 Elsevier Inc. 313
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Renal Cyst Development in Fh1-Deficient MiceFigure 3. Mice with Renal-Specific Fh1
Knockout Develop Multiple Tubule-
Derived Cysts
(A) The figure shows gross features of a bi-
sected kidney from an Fh1fl/fl Ksp1.3/Cre
mouse aged 12 months.
(B) The figure (scale bars, 250 mm) shows H&E
staining of typical wild-type and cystic Fh1
knockout kidneys. Thp immunostaining of
wild-type and knockout kidneys indicates
origin of this cyst from the thick ascending
limb of the loop of Henle. Aquaporin2 immu-
nostaining of wild-type and knockout kidneys
indicates that the cyst is not collecting-duct
derived.
(C) A cut-off of >0.1 mm diameter was used
to classify a lesion as a cyst, and >0.5 mm
diameter was used to classify a cyst as macro-
scopic. The median numbers of macroscopic
and microscopic cysts detected in hemisec-
tions of kidneys of eight knockout (Fh1fl/fl Ksp1.3/Cre) and eight control mice are shown (for the microscopic cysts, p = 0.0006; for the macro-
scopic cysts, p = 0.0008, Mann-Whitney test). Kidney size did not differ significantly between the two groups of mice (details not shown). y error
bars indicate ±SEM.expression of Hif1a, Hif2a, glucose transporter 1 (Glut1),
and carbonic anhydrase IX (Caix) proteins and separately
assessed using ISH for Vegf and transforming growth fac-
tor a (Tgfa) mRNA expression. Hif1a was overexpressed
(mean = 53% positive cyst nuclei, median = 50%, IQR =
48%–57% [Figures 6 and 7]) in the epithelia of all renal
cysts from knockout animals, compared with noncystic
kidney from the same animals, in which only occasional
expression (<1% of nuclei) was found (Figure 6). Nuclear
Hif2a overexpression (Figure 6) was also found consis-
tently in cysts from the knockouts, although in a lower pro-
portion of cyst epithelial cells (mean = 27% positive cyst
nuclei, median = 24%, IQR = 21%–31%) than Hif1a (Fig-
ure 6); again only occasional Hif2a expression was found
in the noncystic kidney. There was no association (positive
or negative) between Hif1a and Hif2a expression (details
not shown). Glut1 and Vegf overexpression were found
wherever there was Hif1a overexpression (Figure 6), con-
sistent with previous reports of these being Hif1a targets
(Boado and Pardridge, 2002; Levy et al., 1996). Interest-
ingly, however, expression of the HIF1a target Caix was
almost undetectable in the cysts. Moreover, the Hif2a-
target Tgfa was not expressed in any cyst, even those
with positive Hif2a staining. In the microcysts from the con-
trol animals, few nuclei (<5%) showed nuclear expression
of Hif1a, Hif2a, or their targets (Figure 6); noncystic renal
tissue from the controls showed very occasional expres-
sion (<1% of nuclei) of either protein. Although the TUNEL
assay showed no difference between the knockout cysts
and wild-type microcysts as regards apoptotic cells, the
knockout cysts did show evidence of greater proliferation
(p = 0.0009, Mann-Whitney test), since Ki67 staining was
more frequent (median = 7.5% cells) compared with the
wild-type (median = 2.0% of cells) (Figure 6).
In order to corroborate our in vivo data, we inactivated
Fh1 by expression of Cre recombinase in Fh1fl/ embry-
onic stem (ES) cells from our mice. Replicate experiments
showed that, after 48 hr, the Cre-transfected cells, but not314 Cancer Cell 11, 311–319, April 2007 ª2007 Elsevier Inc.controls, had greatly decreased expression of Fh1 that
was accompanied by increased levels of Hif1a (Figure 7).
So as to provide evidence for a common pathway of
pathogenesis in Fh1/ murine cysts and human tumors
with biallelic FH mutations, we analyzed five HLRCC
type II papillary RCCs (Alam et al., 2005; Kiuru et al.,
2001; Tomlinson et al., 2002) for expression of both HIFa
isoforms and the target gene products GLUT1 and CAIX.
As in the murine renal cysts, both HIF1a and HIF2a were
overexpressed, with the latter again seen in fewer nuclei
(median = 24% cancer nuclei positive for HIF1a, IQR =
19%–34%; median = 9% nuclei positive for HIF2a, IQR =
6%–11%). GLUT1 protein was highly expressed when
HIF1awas overexpressed (Figure 6). Similarly to the cysts,
CAIX expression was minimal.
DISCUSSION
Our in vivo model has shown that Fh1 inactivation in the
kidney causes the development of abnormally large and
numerous cysts that have monoclonal origins and, even
at the earliest stages, have acquired activation of the hyp-
oxia pathway. Both HIF1a and HIF2a expression are found
in these cysts, although the former predominates. It seems
most plausible that activation of the hypoxia pathway is the
cause of the cysts, probably through moderately increased
cell proliferation. It is notable that inactivation of Vhl in the
mouse kidney using a different mechanism of Cre expres-
sion also causes cystic disease, albeit in a minority of ani-
mals (Rankin et al., 2006). Moreover, both VHL and HLRCC
patients develop multiple renal cysts, and these are likely
to be premalignant lesions (Mandriota et al., 2002); it is en-
tirely possible that if the cysts of our mice had not caused
renal failure, progression to dysplasia and subsequent
malignancy would have occurred. Pseudohypoxic drive
is widely considered to contribute, at least in part, to tu-
morigenesis in VHL disease, HLRCC, HPGL, and many
sporadic cancers. Although assay of PHD activity was
Cancer Cell
Renal Cyst Development in Fh1-Deficient Micenot possible for technical reasons in the renal cysts of our
mice, our data provide further support for the model in
which HIF1a stabilization in HLRCC (and HPGL) tumors
occurs via inhibition of PHDs by fumarate and/or succinate
accumulation (Isaacs et al., 2005; Pollard et al., 2005b;
Selak et al., 2005). It remains possible that inhibition of
other dioxygenases, such as procollagen prolyl hydroxy-
lases, contributes to tumorigenesis in HLRCC.
Our data suggest that pseudohypoxic drive resulting
from FH inactivation differs from that caused by VHL inac-
tivation. In our mice and HLRCC cases, nuclear expres-
sion of HIF1a was greater than that of HIF2a, even though
increased HIF2a in many human tumors is associated with
enhanced growth and progression (Raval et al., 2005; Xia
et al., 2002; Yoshimura et al., 2004). In Vhl knockout mice,
Hif2a is overexpressed in liver tumors, but in renal cysts
(Rankin et al., 2005; Rankin et al., 2006), Hif2a expression
has not been detected, nor has Hif1a expression been
described. Interestingly, genetic evidence suggests that
Hif1a overexpression is not obligatory for renal cyst devel-
opment in Vhl mutant mice, since cysts can form on a
Figure 4. Comparison of Representative Serial Sections
Shows Homozygous Knockout of Fh1 in Epithelial Lining of
Renal Cysts
(A) Control (Fh1fl/fl; Ksp1.3-Cre/) and knockout mice (Fh1fl/fl; Ksp1.3-
Cre+/) stained with H&E and analyzed for expression of Fh1 mRNA.
Note absence of Fh1 expression in the knockout cystic epithelium
(b-actin-positive control not shown). Scale bar, 500 mm for each panel.
(B) Sections of a complex cyst in a knockout animal: expression of
b-actin mRNA is present in the cyst epithelium, but Fh1 mRNA expres-
sion is absent as indicated by the arrow. Scale bar, 250 mm for each
panel.
(C) Results of laser-capture dissection and genomic PCR analysis of
this cyst, with one band (1 flox) indicating the presence of one loxP
site and homozygous deletion of Fh1; this is compared with the two
bands in the renal cortex (2 flox, indicating the presence of two loxP
sites, and 1 flox) owing to the presence of both targeted and deleted
Fh1 alleles.Hif1a/ background. CCRCCs in VHL patients express
CAIX strongly (Kivela et al., 2005; Wykoff et al., 2000),
and CAIX immunostaining has been used for the identifi-
cation of early, premalignant renal lesions in VHL disease
(Mandriota et al., 2002). Our murine renal cysts and
HLRCC tumors, however, revealed very low CAIX expres-
sion and no correlation with expression of HIF1a or HIF2a.
VHL and FH inactivation may therefore have differing
effects on HIF stabilization and the expression of down-
stream target genes, perhaps helping to explain the differ-
ent tissue specificity and tumor spectrum in VHL disease
and HLRCC.
The genetic pathway of renal carcinogenesis in HLRCC
involves germline inactivation of one FH allele and somatic
inactivation of the other; there is very little evidence to
show that somatic inactivation of both FH alleles occurs
in sporadic RCCs. We have shown that inactivation of
Fh1 in the kidney causes activation of the hypoxia path-
way and modestly increased cellular proliferation that re-
sults in numerous, often macroscopic cysts. This pheno-
type resembles that found in some Vhl mutant mice. The
lesions in our mice were probably derived from the collect-
ing ducts and thick ascending limb of the loop of Henle,
the former corresponding to the probable site of origin of
at least some of the cancers in HLRCC. The finding of fre-
quent nuclear HIF overexpression in the cysts of our Fh1
knockout animals strongly suggests that FH deficiency
is a direct cause of the HIF stabilization found in HLRCC
tumors. This contention is further supported by the in vitro
Cre-mediated inactivation of Fh1 and subsequent overex-
pression of Hif1a in our murine Fh1fl/ ES cells. It is also
plausible, at least in some cases, that a simple cyst /
complex cyst/dysplastic cyst / carcinoma exists for
HLRCC, as it probably does for VHL disease, with FH in-
activation as the initiating event in this pathway. While
other (epi)genetic events are almost certainly required
Figure 5. Enzyme Cytochemistry for Cytochrome c Oxidase
Subunit 1
Enzyme cytochemistry for cytochrome c oxidase subunit 1 (A–C)
shows absence of expression in central cyst (blue) and expression
(brown) in surrounding cysts and normal kidney from an Fh1/ knock-
out animal. Scale bar, 250 mm for all panels.Cancer Cell 11, 311–319, April 2007 ª2007 Elsevier Inc. 315
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Renal Cyst Development in Fh1-Deficient MiceFigure 6. Analysis of Proliferation and Hypoxia-Related Genes in Fh1 Null Renal Cysts and Human Type II Papillary Carcinomas
(A) Fh1 wild-type kidney shows weak cytoplasmic staining of Hif1a and Hif2a, and absence of nuclear positivity. Scale bar, 250 mm for all panels.
(B) Fh1 knockout renal cysts show strong nuclear expression of Hif1a in the epithelial layer. Hif2a nuclear staining occurs at a lower frequency than
that of Hif1a in cyst epithelium. The protein product of the Hif1-target gene Glut1 is expressed in the epithelial layer, as is Vegf mRNA (b-actin control
not shown). High vascularity around the lesion is indicated by the endomucin immunostaining. Scale bar, 125 mm for all panels.
(C) The proportions of cyst cells expressing nuclear Hif1a and Hif2a in ten random high-power fields from kidneys derived from each of three control
and four knockout mice are shown. The differences between the knockouts and controls were highly statistically significant (p < 0.0001 for both Hif1a
and Hif2a, Mann-Whitney test). y error bars indicate ± SEM.
(D) A representative renal cyst from an Fh1 knockout animal shows cells (arrows) with Ki67 immunostaining. Wild-type kidney (not shown) has very
little Ki67 expression. Scale bar, 250 mm for all panels.
(E) Human HLRCC type II papillary renal carcinoma shows strong nuclear expression of HIF1a and overexpression of GLUT1. Scale bar, 250 mm for all
panels.for renal cancer in HLRCC, our mouse model may provide
a useful model for testing potential therapies for RCC.
EXPERIMENTAL PROCEDURES
Generation and Husbandry of Mice
Following generation of the targeting construct, linearization, and elec-
troporation into 129Sv/J ES cells, stable integrants were selected in
0.2 mgml1 Geneticin G418 medium. Homologous recombinants
were identified initially by PCR and subsequently by Southern blot
analysis. Targeted ES cells were injected into C57/BL6 blastocysts.
The Cancer Research UK Transgenic and Ethics committees ap-
proved all procedures involving live animals, and experiments were un-
dertaken in accordance with the Home Office guidelines and licensing
regulations (project license number: 70/6018).
DNA Extraction
DNA extraction from ES cells and tail clippings was carried out after
overnight digestion at 55C in extraction buffer (100 mM EDTA [pH
8.0], 50 mM TRIS-HCl [pH 8.0], 100 mM NaCl, 1% SDS [w/v], and
1.0 mgml1 proteinase K). DNA was precipitated by adding isopropa-
nol, washed twice in 70% ethanol (v/v), and resuspended in TE (pH 8.0).
Mouse and ES Cell Genotyping
ES cell clones were screened for 50 and 30 site-specific genomic inte-
gration of the targeting construct using a PCR-based assay and LA-
Taq (Takara). PCR genotypes to assay Flp- and Cre-mediated recom-316 Cancer Cell 11, 311–319, April 2007 ª2007 Elsevier Inc.bination, and genotyping of eFlp and Cre expression mice were carried
out using standard conditions. For the genotyping of Fh1 to distinguish
between wild-type, null, and floxed alleles, a common forward primer
(50-GCTCAGTCACCCATCCAAAT-30) and differential reverse primers
(50-ACCCTGCTAGGTGTCACCAC-30 and 50-CCTGGCACTGCAGACT
ACAA-30) were used. Further details of genotyping are available from
the authors on request.
Southern Blotting
Southern blotting of DNA from ES cell clones and mice was performed
using standard procedures. In brief, 11 mg of DNA was digested with
XcmI, and the DNA was electrophoresed through a 1% agarose gel
for 16 hr at 50 V. The gel was depurinated, denatured, and neutralized,
and DNA was transferred overnight to Hybond N+ nitocellulose mem-
brane (Amersham). The membrane was UV crosslinked. PCR was
used to generate two probes, one of 498 bp with homology to exon
5 of the Fh1 gene and another of 350 bp derived from the neomycin
cassette of the targeting vector. The probes were labeled with a32-
dCTP and denatured, before being hybridized to the membrane over-
night at 65C in a rotating oven. The membrane was washed, exposed
to film (Kodak) overnight at 80C, developed, and quantitated by
signal intensity of specific-sized bands.
Immunohistochemistry
Processing of tissue and immunochemistry was performed using stan-
dard methods. In brief, all mouse tissues were fixed in neutral-buffered
10% formalin for 24 hr. Antigen retrieval was performed by microwav-
ing in citrate buffer (pH 6.0) for 10–15 min. Primary antibodies: laminin
Cancer Cell
Renal Cyst Development in Fh1-Deficient Mice(Abcam), Oct4 (CeMines), THP (Biogenesis), aquaporin2 (R&D Sys-
tems), endomucin (kind gift from Dr Vestweber, Germany), and Ki67
(Dako). Immunohistochemistry for Hif1a, Hif2a (Epas1), Glut1, and
Caix was carried out as previously described (Talks et al., 2000), and
the apoptosis was assessed using the DeadEnd colorimetric TUNEL
kit (Promega). Expression was assessed by three independent ob-
servers (P.J.P., M.D., and D.S.) as follows. For aquaporin2, Caix,
Glut1, and Thp, cysts were scored as showing positive or negative
expression. For Ki67 and TUNEL, positive nuclei were counted per
high-power field (3400) in both wild-type and knockout kidneys, and
the percentage positivity was calculated per cyst. For Hif1a and Hif2a,
each section was initially assessed for nuclear expression. The num-
bers and proportions of positive nuclei (Hif1a and Hif2a) per cyst
were calculated in whole kidney sections from eight animals (four
knockouts, four control). For the five HLRCC type II papillary RCC, total
and positive nuclei were counted in ten high-power fields (3400), and
the percentage of positive nuclei was determined for each HIF isoform.
Unpaired normal kidney and stromal cells within the tumor sections
were used as negative controls.
In Situ Hybridization
In situ hybridization was carried out using 4 mm serial sections from the
same formalin-fixed, paraffin-embedded specimens as used for
immunohistochemistry. The murine Fh1 probe (230 bp) was PCR
amplified from cDNA using the primers 50- CGGGGTACCTGAAGCG
AGCTGCTGCTGAAGTA-30 and 50-CCGGAATTCCACAGGCTTCTT
GCTGCCAAGTT-30 (restriction sites underlined), cloned into pGEM-
Figure 7. Fh1 Knockout in Embryonic Stem Cells Causes
Upregulation of Hif1a
(A) Visualization of eGFP in ES cells 48 hr posttransfection with pCre-
IREShrGFPII using low-power light microscopy.
(B) Western blotting of FACS-sorted ES cells showing HIf1a, Fh1, and
b-actin (loading control). Note that low levels of endogenous Hif1a are
present in wild-type cells and in Fh1fl/ cells in the absence of Cre. Cre-
mediated removal of the targeted Fh1 allele was confirmed by genomic
PCR (not shown) and consistently resulted in very little Fh1 protein and
greatly increased (>5-fold) Hif1a.3Z (Promega) using EcoRI and KpnI, and linearized with BamHI. Anti-
sense RNA was generated by T7 polymerase. For hybridization con-
trol, a b-actin probe (414 bases) was generated from DraI-linearized
pSP73 (Promega) containing clone hbA-10. Vegf and Tgfa ISH have
previously been described (Goldenring et al., 1996; Huminiecki et al.,
2001). a35S-UTP labeling, hybridization, and processing for all probes
were performed as previously described (Poulsom et al., 1998). Signal
intensity was scored by two independent observers (P.J.P. and R.P.)
as absent, weak, moderate, or strong for all sections for which b-actin
signal passed quality control threshold.
Laser-Capture Microdissection
Kidney sections (5 mm) were stained with methylene green, and renal
cortex and cysts were isolated using LCM (Palm@Robo V2.2,
P.A.L.M Microlaser Technologies) at3400 magnification and illumina-
tion (Carl Zeiss, HAL 100). DNA was extracted using the PicoPure kit
(Arcturus) using the manufacturer’s protocol. DNA was PCR amplified
as described in the mouse genotyping methods.
Enzyme Histochemistry
Frozen sections were cut at a thickness of 12 mm. Sequential cyto-
chrome c oxidase and succinate dehydrogenase (used to highlight
any deficiencies in cytochrome c oxidase) histochemistry was per-
formed as previously described (Taylor et al., 2003). We found no
evidence that Fh1 deficiency had a detrimental effect on this assay,
as the great majority of Fh1/ cysts showed normal expression of
cytochrome c oxidase, as expected. Briefly, air-dried sections were
incubated with a cytochrome c oxidase medium containing 100 mM
cytochrome c, 20 mg/ml catalase, and 4 mM diaminobenzidine tetra-
hydrochloride in 0.2 M phosphate buffer (pH 7.0), all sourced from
Sigma Aldrich (Poole, UK) for a maximum of 2 min at 37C (or until
no increase in staining intensity was observed). Sections were then
washed in phosphate-buffered saline buffer (pH 7.4) (PBS) three times
for 5 min and then incubated in SDH medium (130 mM sodium succi-
nate, 200 mM phenazine methosulphate, 1 mM sodium azide, and
1.5 mM nitroblue tetrazolium in 0.2 M phosphate buffer [pH 7.0]).
ES Cell Culture and Transfection
Fh1fl/ ES cells were derived from blastocysts (E3.5) taken from mat-
ings between Fh1fl/fl and Fh1fl/ mice using standard procedures
(Nagy et al., 2003). Cells were maintained in culture under standard
conditions (Nagy et al., 2003). For transfections, ES cells were trypsi-
nized and then plated on gelatin-coated tissue culture plates 24 hr
prior to transfection. The cDNA coding sequence for Cre recombinase
was cloned into pIREShrGFPII (Stratagene, CA, USA), in which GFP is
expressed using an IRES, using standard procedures. Cells were
transfected with 4 mg of pCre-IREShrGFPII or pIREShrGFPII with 1.5
mg of Lipofectamine 2000 (Gibco-BRL, MD, USA). The transfected
cells were harvested after 48 hr and viewed under a low-light micro-
scope (Nikon) to assay fluorescence. Cells were trypsinized, centri-
fuged, suspended in chilled PBS, and subjected to fluorescence-
activated cell sorting (FACS) analysis on the basis of GFP expression
using a MOFLOW flow cytometer (Dakocytomation, CO, USA).
Western Blotting
FACS-sorted cells were pelleted and washed twice in PBS, and protein
was extracted using standard methods as previously described
(Pollard et al., 2005b). Fifty micrograms of total protein was resolved
through Tris-Acetate gels at constant current (30 mA) and transferred
to PDVF membrane using the NuPage/iBlot system (Invitrogen) follow-
ing the manufacturer’s protocol. Antibodies (anti-Hif1a [Abcam] 1/
1000, anti-b-actin [Sigma] 1/1000, and anti-fumarase [Nordic] 1/400)
were applied in 3% dried milk, constituted in PBS, and hybridized
overnight at 4C. Secondary antibody (Dako) was applied 1/5000 for
45 min at room temperature. Proteins were detected using the ECL
technique (Amersham Pharmacia, UK) and visualized by scanning
and densitometry, comparing the Hif1a and Fh1 levels to the b-actin
control.Cancer Cell 11, 311–319, April 2007 ª2007 Elsevier Inc. 317
Cancer Cell
Renal Cyst Development in Fh1-Deficient MiceStatistical Analysis
Expression levels of genes and proteins were compared in test and
control animals or cells using the Mann-Whitney test.
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